UNSPSC 51343203: Ritonavir

This classification denotes a protease inhibitor with the molecular formula C37H48N6O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O3J8G9O825, chemically known as 2,4,7,12-tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (5s-(5r*,8r*,10r*,11r*))- but generally known as ritonavir, which bears US NIH Compound Identifier 60954.

UNSPSC 51343203 Ritonavir is a Commodity code that nominally covers a specific antiretroviral pharmaceutical, but recent state and local solicitations tagged with this code show little activity directly aligned with that product. Instead, the tagged opportunities span medical and first aid supplies, naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and exploratory direct-to-manufacturer prescription programs — a divergence that signals either miscoding or use of the code as a placeholder for broader pharmaceutical procurement. State and local governments buying under this code include county health departments, municipal fire departments, state health commissions, and multistate cooperative purchasing alliances such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). Issuing bodies range from single jurisdictions (Seminole County, Florida; City of Tampa) to coordinated procurement vehicles serving multiple states and local agencies.

Recent activity spans Florida, Texas, and Minnesota. Representative opportunities include Seminole County, Florida issuing an IFB (Solicitation IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives; the City of Tampa posting an IFB (26P00145, due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, estimated at $700,000.00 and designated as a sheltered market with a 5 percent SLBE bid discount; the Minnesota Department of Administration's Office of State Procurement administering MMCAP issuing an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with a July 1, 2026 effective date for awarded vendors; and the Texas Health and Human Services Commission posting an RFI (HHS0017013, due April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program. The code shows sparse direct pharmaceutical procurement activity and may warrant re-evaluation for relevance to state and local opportunity streams.